Cancer risk in patients with FH deficiency is significant, due to its key role in HLRCC syndrome and in the lifetime risk of developing renal cell carcinoma (as high as 15–30%) [21,22]. The gene discussed is FH; the disease is hereditary clear cell renal cell carcinoma.